10-K
Annual Report
ADIAL PHARMACEUTICALS, INC.
ADIL
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
25 line items · 2 periods
XBRL
| Item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
Current Assets: | ||
Cash and cash equivalents | 5,881,217 | 3,750,525 |
Prepaid expenses and other current assets | 299,666 | 308,239 |
Total Current Assets | 6,180,883 | 4,058,764 |
Equity Method Investments | 3,320,934 | 1,676,591 |
Intangible assets, net | 2,784 | 3,348 |
Equity method investment | 489,700 | 981,830 |
Equity Method Investments | 489,700 | 981,830 |
Total Assets | 6,673,367 | 5,043,942 |
Current Liabilities: | ||
Accounts payable | 655,207 | 250,130 |
Related Party | — | 48,272 |
Accrued expenses | 741,702 | 677,456 |
Total Current Liabilities | 1,396,909 | 975,858 |
Equity Method Investments | 396,899 | 537,303 |
Total Liabilities | 1,396,909 | 975,858 |
Stockholders’ Equity | ||
Common Stock, 100,000,000 shares authorized with a par value of $0.001 per share, 1,111,124 and 258,940 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1,111 | 259 |
Additional paid in capital | 95,247,841 | 86,063,148 |
Accumulated deficit | (89,972,494) | (81,995,323) |
Total Stockholders’ Equity | 5,276,458 | 4,068,084 |
Accumulated Deficit | (89,972,494) | (81,995,323) |
Additional Paid In Capital | 95,247,841 | 86,063,148 |
Common Stock | 1,111 | 259 |
Total Liabilities and Stockholders’ Equity | 6,673,367 | 5,043,942 |